A systematic review of the present and future of non-alcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the Western world. Ongoing research has furthered our understanding of NAFLD, the nature of progression of this disease, and its impact on morbidity and mortality. An active form of NAFLD is non-alcoholic steatohepatitis (NASH); it is the most severe subtype, without any current recommended therapies, according to the European Medicines Agency. The development of new therapies presents challenges, notably due to the slow progression of NASH and the clinically relevant endpoints. Correlating new data with effective treatment regimens is an emerging challenge, which will increase our understanding of the factors affecting the NAFLD course. This can enable more appropriate non-invasive prognostic assessments, which can focus on specifically at-risk NAFLD populations for tailored individual treatment. This review article aims to highlight the current developments in the field of NAFLD: pathogenesis, epidemiology, diagnosis, clinical features, and available treatment, including novel targets and therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.12.012 · Cited by 3,119
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Inflammasomes in health and disease
Strowig, T., Henao-Mejia, J., Elinav, E., & Flavell, R. (2012) · Nature · doi:10.1038/nature10759 · Cited by 2,230 · cited 1×
“TLRs are predominantly expressed on sentinel cells, with TLR4 mediating the recruitment of monocytes and macrophages to the liver [12].”
BackgroundArmstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease
Miele, L., Valenza, V., La Torre, G., Montalto, M., Cammarota, G., Ricci, R., Mascianà, R., Forgione, A., Gabrieli, M. L., Perotti, G., et al. (2009) · Hepatology · doi:10.1002/hep.22848 · Cited by 1,434
The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome
Lim, J. S., Mietus-Snyder, M., Valente, A., Schwarz, J.-M., & Lustig, R. H. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.41 · Cited by 771 · cited 1×
“This diet may include high intakes of red and processed meats, refined sugars, saturated fats, refined grains, high-fat dairy, and sugar-laden fructose drinks [33, 34].”
BackgroundRatziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann–Heurtier, A., Serfaty, L., Podevin, P., Lacorte, J., Bernhardt, C., Bruckert, E., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.078 · Cited by 625 · cited 1×
“The randomized placebo controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) trial resulted in 47% of NASH patients having a significant (> 30%) reduction in steatosis after a period of 12 months of treatment, with 38% achieving normalization of ALT values [65].”
MethodSantos, C. X. C., Tanaka, L. Y., Wosniak, J., & Laurindo, F. R. M. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2625 · Cited by 572 · cited 1×
“ER stress constitutes a cellular process that is triggered by pathologies which disturb the folding of proteins [15].”
BackgroundSayiner, M., Koenig, A., Henry, L., & Younossi, Z. M. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.10.001 · Cited by 529
Smoking cessation and weight gain
Filozof, C., Fernández Pinilla, M. C., & Fernández‐Cruz, A. (2004) · Obesity Reviews · doi:10.1111/j.1467-789x.2004.00131.x · Cited by 519 · cited 1×
“A further lifestyle risk factor is smoking, as tobacco is known to increase susceptibility to the development of insulin resistance [38].”
BackgroundLiver stiffness: a novel parameter for the diagnosis of liver disease
Mueller, S. (2010) · Hepatic Medicine: Evidence and Research · doi:10.2147/hmer.s7394 · Cited by 434
Svegliati‐Baroni, G., Saccomanno, S., Rychlicki, C., Agostinelli, L., De Minicis, S., Candelaresi, C., Faraci, G., Pacetti, D., Vivarelli, M., Nicolini, D., et al. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02462.x · Cited by 405 · cited 1×
“GLP-1 agonists have been shown to reduce both hepatic steatosis and necroinflammation [66-69].”
BackgroundEffects of probiotics on nonalcoholic fatty liver disease: A meta-analysis
Ma, Y.-Y. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i40.6911 · Cited by 352
Effect of aerobic exercise training dose on liver fat and visceral adiposity
Keating, S. E., Hackett, D. A., Parker, H. M., O’Connor, H. T., Gerofi, J. A., Sainsbury, A., Baker, M. K., Chuter, V. H., Caterson, I. D., George, J., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.022 · Cited by 313 · cited 1×
“In patients with obesity, exercise is further complicated by musculoskeletal problems that manifest biomechanically [53].”
BackgroundEffects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes
Sathyanarayana, P., Jogi, M., Muthupillai, R., Krishnamurthy, R., Samson, S. L., & Bajaj, M. (2011) · Obesity · doi:10.1038/oby.2011.152 · Cited by 124
Hepatokines and non-alcoholic fatty liver disease
Lebensztejn, D. M., Flisiak-Jackiewicz, M., Białokoz-Kalinowska, I., Bobrus-Chociej, A., & Kowalska, I. (2016) · Acta Biochimica Polonica · doi:10.18388/abp.2016_1252 · Cited by 90 · cited 1×
“Fetuin-A is a biomarker of NAFLD, and is increased in NAFLD patients, this hepatokine suppresses the autophosphorylation of insulin receptors in the skeletal muscles and liver, as well as promoting inflammatory cytokines in monocytes and adipocytes whilst simultaneously activating Toll-like receptors (TLRs) 4 [11].”
BackgroundHBx-Induced Hepatic Steatosis and Apoptosis Are Regulated by TNFR1- and NF-κB-Dependent Pathways
Kim, J. Y., Song, E. H., Lee, H. J., Oh, Y. K., Choi, K.-H., Yu, D.-Y., Park, S. I., Seong, J.-K., & Kim, W.-H. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.02.016 · Cited by 71 · cited 1×
“LXR induces the expression of target genes such as carbohydrate regulatory element binding protein (ChREBP), sterol regulatory element binding protein 1c (SREBP-1c), and fatty acid synthase [6, 7].”
Background
Cited by
Atabaki-Pasdar, N., Ohlsson, M., Viñuela, A., Frau, F., Pomares-Millan, H., Haid, M., Jones, A. G., Thomas, E. L., Koivula, R. W., Kurbasic, A., et al. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003149 · Cited by 97
Jang, A.-R., Jung, D.-H., Lee, T.-S., Kim, J.-K., Lee, Y.-B., Lee, J.-Y., Kim, S.-Y., Yoo, Y.-C., Ahn, J.-H., Hong, E.-H., et al. (2024) · Nutrition · doi:10.1016/j.nut.2024.112565 · Cited by 20
Metadata
- Authors
- Lucas, C., Lucas, G., Lucas, N., Krzowska-Firych, J., & Tomasiewicz, K.
- Venue
- Clinical and Experimental Hepatology
- Publisher
- Termedia Sp. z.o.o.
- Published
- 2018
- Volume
- 4
- Issue
- 3
- Pages
- 165-174
- ISSN
- 2392-1099 (ISSN-L)
- OpenAlex
- W2895600813
- Cited by
- 52
- References
- 22
- FWCI
- 1.40
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.